3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
11
Neoplasms
3
HER2-positive Breast Cancer
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Endometrial Neoplasms
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Melanoma
1
Malignant Solid Neoplasm
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Hemangiosarcoma
1
HR+/HER2+ Early Breast Cancer
1
Glioma
1
Interventions
Oxaliplatin
8
Fluorouracil
8
Nivolumab
7
Leucovorin
7
Paclitaxel
6
Capecitabine
5
Taxes
4
Specimen Handling
4
pembrolizumab
3
Trastuzumab
3
Ramucirumab
3
Magnetic Resonance Spectroscopy
3
Cisplatin
3
zimberelimab
2
zanidatamab
2
Radiotherapy
2
Folfox protocol
2
Carboplatin
2
zolbetuximab
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
tislelizumab
1
quemliclustat
1
obeticholic acid
1
futibatinib
1
dehydroftorafur
1
cixutumumab
1
balstilimab
1
Saline Solution
1
Radiofrequency Ablation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Adenocarcinoma Of Esophagus
×
pertuzumab
×
30 days
×
Clear all
No trials found.